Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
3(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_1
2
17%
Ph phase_2
1
8%
Ph phase_3
8
67%

Phase Distribution

3

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
8(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(9)

Detailed Status

Completed9
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (8.3%)
Phase 12 (16.7%)
Phase 21 (8.3%)
Phase 38 (66.7%)

Trials by Status

active_not_recruiting325%
completed975%

Recent Activity

3 active trials
Showing 5 of 12
active_not_recruitingphase_3

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06527404
active_not_recruitingphase_3

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05882877
completedphase_1

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

NCT06438263
completedphase_3

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738
completedphase_1

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

NCT06214481
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06527404Phase 3

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Active Not Recruiting
NCT05882877Phase 3

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Active Not Recruiting
NCT06438263Phase 1

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Completed
NCT05704738Phase 3

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Completed
NCT06214481Phase 1

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

Completed
NCT05891119Early Phase 1

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Completed
NCT06376045Phase 2

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Active Not Recruiting
NCT05633355Phase 3

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Completed
NCT05724199Phase 3

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

Completed
NCT05398445Phase 3

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

Completed
NCT05899816Phase 3

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Completed
NCT05651711Phase 3

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12